

## AGENDA

### *Uniform Formulary Beneficiary Advisory Panel 27 June 2013 @ 0900 AM*

*Naval Heritage Center Theater  
701 Pennsylvania Ave. NW., Washington DC 20004*

- **Administrative Meeting (BAP members only @ 8:30 AM-9:00 AM)**
- **Sign-In**
- **Welcome and Opening Remarks**
- **Public Citizen Comments**
- **Therapeutic Class Reviews**

*Members of the DoD Pharmacoeconomic Center will present relative clinical and cost effective analyses along with the DoD Pharmacy & Therapeutics Committee recommendations for the Uniform Formulary.*

*The Committee made recommendations for the following drug classes during the May 2013 meeting:*

- *Drug Class Reviews:*
  - *Anti-Gout Medications*
  - *Chronic Obstructive Pulmonary Disease Agents – Pulmonary II Drugs*
- *Designated Newly Approved Drugs:*
  - *Non-Insulin Diabetes Drugs – Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors – canagliflozin (Invokana )*
- *Utilization Management Issues*
  - *Prior Authorization Criteria*
    - *Proton Pump Inhibitors: Generic Pantoprazole – move to preferred therapy*
    - *Antilipidemics 2 – Prescription fish oil: Icosapent ethyl (Vascepa) – Prior Authorization*

- **Panel Discussions**

*The Uniform Formulary Beneficiary Advisory Panel will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will discuss the recommendation and vote to accept or reject the recommendations. The Panel will provide comments on their vote as directed by the Panel Chairman.*